Ropeginterferon alfa-2B
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 115 publications
Sustained molecular response after discontinuation of ropeginterferon alfa-2b in a young patient with polycythemia vera
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 29, 2026
Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 29, 2026
Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 29, 2026
Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera.
Journal: International heart journal
Published: November 30, 2025
Ropeginterferon alfa-2b in polycythemia vera: redefining disease control through molecular targeting.
Journal: Expert review of anticancer therapy
Published: November 19, 2025
Real-World Retrospective Report on the Efficacy, Tolerability, and Molecular Responses to Ropeginterferon-α2b in Patients with Myeloproliferative Neoplasms.
Journal: Journal of clinical medicine
Published: November 06, 2025
Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.
Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.
Journal: Internal medicine (Tokyo, Japan)
Published: October 29, 2025
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
Journal: Leukemia
Published: October 28, 2025
Pharmacologic management of ET: established therapies and emerging agents.
Journal: Expert opinion on pharmacotherapy
Published: October 27, 2025
Last Updated: 04/28/2026